Medulloblastoma: Clinical Trials

147 trials for Medulloblastoma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

84 completed, 19 terminated, 17 recruiting, 12 active not recruiting. 147 Phase 1, 27 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 1147Completed 84, Terminated 19, Recruiting 17, Active not recruiting 12, Withdrawn 7, Unknown 6, Not yet recruiting 1, Suspended 1
Phase 227Completed 11, Terminated 7, Recruiting 5, Active not recruiting 2, Suspended 1, Unknown 1

Follow Medulloblastoma: new trials by email Literature Review of Medulloblastoma trials Research Report on Medulloblastoma

Trials (filtered) newest first · largest first

All 147 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Axitinib and Oral Metronomic Etoposide for Pediatric Children and AYA Refractory/Relapsing Medulloblastoma and Ependymoma
administration of axitinib in combination with etoposide - Medulloblastoma, Ependymoma
Phase 1 / Phase 2RecruitingAssistance Publique Hopitaux De Marseille402032-02-012026-11-12
PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline Glioma/High-grade Glioma, Medulloblastoma, and Ependymoma
PEP-CMV vaccine, Tetanus booster, Nivolumab - Diffuse Midline Glioma, Diffuse Midline High-grade Glioma
Phase 1 / Phase 2SuspendedWashington University School of Medicine682026-11-302026-10-30
B7-H3.CD28Z.CART in CNS Neoplasms
B7-H3.CD28Z.CART, Fludarabine, Cyclophosphamide - Central Nervous System Neoplasms, Brain Tumor
Phase 1RecruitingRobbie Majzner702026-09-012026-09-03
Study of CDK8 Inhibitor RVU120 in Combination With Everolimus in Children With Recurrent or Progressive Group 3 or 4 Medulloblastoma
RVU120, Everolimus (Afinitor) tablets - Medulloblastoma Recurrent, Medulloblastoma
Phase 1Not yet recruitingBożenna Dembowska Bagińska482026-09-012026-10-08
Liothyronine in Combination With BIT Regimen for Medulloblastoma With or Without Minimal Residual Disease
Liothyronine (L-T3), Bevacizumab, Irinotecan - Medulloblastoma, Medulloblastoma, Childhood
Phase 1 / Phase 2RecruitingSabine Mueller, MD, PhD692026-08-212026-09-28
A Study of 177Lu-DTPA-Omburtamab in Children and Adolescents With Brain Cancer or Cancer That Has Spread to the Central Nervous System (CNS)
25 mCi 177Lu- DTPA-omburtamab - Recurrent Medulloblastoma, Refractory Medulloblastoma
Phase 1RecruitingMemorial Sloan Kettering Cancer Center242026-07-022026-10-08
Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors
Becotatug Vedotin - Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Nasopharyngeal Carcinoma
Phase 1RecruitingSun Yat-sen University512026-05-302026-05-13
RNA-lipid Particle (RNA-LP) Vaccines for Recurrent/Progressive Medulloblastoma (MB)
Autologous total tumor mRNA and pp65 full length (fl) lysosomal associated membrane protein (LAMP) mRNA loaded DOTAP liposome vaccine administered intravenously (RNA loaded lipid particles, RNA-LPs) - Recurrent Medulloblastoma
Phase 1RecruitingUniversity of Florida242026-04-242026-11-16
GPC2-CAR T Cell Therapy for Relapsed or Refractory Medulloblastoma in Children and Young Adults
GPC2-CAR T cells, Fludarabine, Cyclophosphamide - Medulloblastoma, Central Nervous System Embryonal Tumor
Phase 1RecruitingStanford University182025-08-282026-10-09
Adoptive T Cell Therapy, DC Vaccines, and Hematopoietic Stem Cells Combined With Immune checkPOINT Blockade in Patients With Medulloblastoma
TTRNA-DC vaccines with GM-CSF, TTRNA-xALT, Td vaccine - Recurrent Group 3 Medulloblastoma, Recurrent Group 4 (Non-SHH/Non-WNT) Medulloblastoma
Phase 1RecruitingUniversity of Florida122025-05-052026-11-02
Atovaquone Combined With Radiation in Children With Malignant Brain Tumors
Atovaquone, Radiation Therapy - High-grade Glioma, Medulloblastoma
Phase 1RecruitingEmory University182025-03-282026-08-03
Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).
Olaparib; 177Lu-DOTATATE - Solid Tumor Cancer, Medulloblastoma
Phase 1 / Phase 2RecruitingFundación de investigación HM252024-09-202026-06-04
Immunotherapy for Malignant Pediatric Brain Tumors Employing Adoptive Cellular Therapy (IMPACT)
Multi-tumor antigen specific cytotoxic T lymphocytes (TSA-T) directed against proteogenomically determined personalized tumor-specific antigens (TSA), Group A Standard-of-Care Backbone Therapy, Group B Salvage Backbone Therapy - Medulloblastoma, Childhood, Atypical Teratoid/Rhabdoid Tumor of CNS
Phase 1RecruitingChildren's National Research Institute122024-09-202026-10-13
Fourth Ventricular Administration of Immune Checkpoint Inhibitor (Nivolumab) and Methotrexate or 5-Azacytidine for Recurrent Medulloblastoma, Ependymoma, and Other CNS Malignancies
Nivolumab, Methotrexate, 5-Azacytidine - Recurrent Ependymoma, Recurrent Medulloblastoma
Phase 1WithdrawnJeffrey Treiber2024-07-152026-01-08
PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications
PLX038 - Glioma, Medulloblastoma
Phase 1 / Phase 2RecruitingNational Cancer Institute (NCI)1462024-01-312026-11-06
GD2-CAR T Cells for Pediatric Brain Tumours
GD2-CART01 (iC9-GD2-CAR T-cells) - Brain Tumor, Pediatric, Medulloblastoma, Childhood
Phase 1RecruitingBambino Gesù Hospital and Research Institute542023-11-092026-09-30
Loc3CAR: Locoregional Delivery of B7-H3-CAR T Cells for Pediatric Patients With Primary CNS Tumors
B7-H3-CAR T cells - Central Nervous System Neoplasms, Atypical Teratoid/Rhabdoid Tumor
Phase 1Active not recruitingSt. Jude Children's Research Hospital292023-04-272026-07-06
Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors
Topotecan, Temozolomide, Ribociclib - Neuroblastoma
Phase 1TerminatedNovartis Pharmaceuticals122022-12-272025-10-10
Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors
LUTATHERA® (Lutetium Lu 177 dotatate) - High Grade Glioma, Meningioma
Phase 1 / Phase 2RecruitingNationwide Children's Hospital652022-11-212026-11-16
A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma
SurVaxM for patients with relapsed or progressive MB, HGG or ependymoma ages ≥10 and ≤21 years, SurVaxM for patients with relapsed or progressive MB, HGG or ependymoma ages ≥1 and <10 years, SurVaxM for patients with non-relapsed DIPG post radiation-therapy ages ≥1 and ≤21 years - Medulloblastoma, Glioblastoma Multiforme
Phase 1Active not recruitingChildren's Oncology Group352022-07-012026-06-02

Showing 20 of 147. Sign in to see all of them.

Narrower conditions

Astrocytoma (76)  ·  Central Nervous System Neoplasms (58)  ·  Oligodendroglioma (57)  ·  Glioma (55)  ·  Ependymoma (49)  ·  Familial ependymoma (48)  ·  Brain Neoplasms (46)  ·  Choroid Plexus Neoplasms (43)  ·  Glioblastoma (43)  ·  Optic Nerve Glioma (42)  ·  Neuroblastoma (40)  ·  Neuroectodermal Tumors, Primitive (35)  ·  Rhabdoid Tumor (33)  ·  Pinealoma (28)

Broader conditions

Neoplasms by Histologic Type (146)  ·  Neoplasms, Glandular and Epithelial (146)  ·  Neoplasms, Nerve Tissue (146)  ·  Neuroectodermal Tumors (143)  ·  Neoplasms, Neuroepithelial (141)  ·  Neoplasms (137)  ·  Neoplasms, Germ Cell and Embryonal (137)  ·  Neoplasms by Site (114)  ·  Neuroectodermal Tumors, Primitive (112)  ·  Nervous System Diseases (106)  ·  Nervous System Neoplasms (106)  ·  Central Nervous System Diseases (96)  ·  Brain Diseases (93)  ·  Glioma (92)  ·  Neoplasms, Complex and Mixed (49)

Interventions

Temozolomide (21)  ·  Filgrastim (14)  ·  Carboplatin (11)  ·  Cyclophosphamide (9)  ·  Etoposide (8)  ·  Granulocyte Colony-Stimulating Factor (7)  ·  Irinotecan (6)  ·  Melphalan (6)  ·  Peripheral Blood Stem Cell Transplantation (6)  ·  Radiotherapy (6)  ·  Thiotepa (5)  ·  Busulfan (4)  ·  Magnetic Resonance Spectroscopy (4)  ·  Vincristine (4)  ·  Vorinostat (4)

Sponsors

National Cancer Institute (NCI) (28)  ·  Pediatric Brain Tumor Consortium (13)  ·  National Institutes of Health Clinical Center (CC) (6)  ·  Novartis Pharmaceuticals (6)  ·  Children's Oncology Group (5)  ·  City of Hope Medical Center (5)  ·  Duke University (4)  ·  M.D. Anderson Cancer Center (4)  ·  Emory University (3)  ·  Masonic Cancer Center, University of Minnesota (3)  ·  OHSU Knight Cancer Institute (3)  ·  Seattle Children's Hospital (3)  ·  St. Jude Children's Research Hospital (3)  ·  Eli Lilly and Company (2)  ·  Giselle Sholler (2)

Countries

United States (131)  ·  Canada (13)  ·  United Kingdom (8)  ·  Australia (7)  ·  Italy (7)  ·  Spain (7)  ·  France (6)  ·  China (5)  ·  Germany (5)  ·  Switzerland (3)  ·  Hong Kong (2)  ·  Japan (2)  ·  Netherlands (2)  ·  Belgium (1)  ·  Denmark (1)

Top investigators

Darell D. Bigner, MD, PhD (4)  ·  Daniel Landi, MD (3)  ·  Maryam Fouladi (3)  ·  Amar Gajjar (2)  ·  Edward A. Neuwelt, MD (2)  ·  Elizabeth Fox, MD (2)  ·  Giles W. Robinson, MD (2)  ·  Giselle Sholler, MD (2)  ·  James Croop, MD, PhD (2)  ·  Jana Portnow, MD (2)  ·  John P. Perentesis, MD (2)  ·  Kim Kramer, MD (2)  ·  Mark W. Kieran, MD, PhD (2)

Results publications

PMID 11410496, PMID 15814645, PMID 16234526, PMID 16533779, PMID 16914576, PMID 17634493, PMID 17941066, PMID 18048828, PMID 18281544, PMID 18281546, PMID 18391430, PMID 18470481, PMID 19065567, PMID 19075272, PMID 19430790, PMID 20044751, PMID 20049936, PMID 20460632, PMID 20847174, PMID 21115653, PMID 21850464, PMID 23554030, PMID 27467121, PMID 28153957, PMID 29181270, PMID 31838007, PMID 31876107, PMID 33047248, PMID 34171339, PMID 34253928, PMID 35395680, PMID 35417530, PMID 35468680, PMID 36371226, PMID 37004712, PMID 37553297, PMID 37640679, PMID 37715730, PMID 38215438, PMID 39775044, PMID 40086048, PMID 41379553, PMID 41798119, PMID 9849694

NIH funding

U01CA081457 (14), U01CA097452 (8), UM1CA081457 (7), P30CA033572 (4), 2023 (2), 2008 (1), 2009 (1), 2019 (1), P30CA008748 (1), P30CA015083 (1), P30CA016087 (1), P30CA016672 (1), P30CA043703 (1), P30CA069533 (1), P30CA124435 (1)